Lucius Pharmaceuticals
International business
Evidence / PK / PD study

Brain exposure in the mapped MCAO context.

Study detail for the 5 mg/kg PK/PD context and normalized exposure visualization.

Conceptual neurovascular scientific plate related to this page
03 / evidence

Read the source constraints first, then the derived display.

pk / pdMCAOpk_pdsource_mapped

Research question

Present source-reported exposure constraints for plasma and brain tissue after dosing.

Methods

ModelMCAO
SpeciesRat
InterventionAildenafil phosphate
Dose5 mg/kg
TimingDose described at 2 h after infarction
ComparatorPlasma versus brain tissue exposure
  • The source summary supports time and relative constraints, not a full absolute concentration series.

Source results

Source result table
EndpointTimepointSource result
Peak time—0.5 h
Residual exposure at 6 h6 hbelow 5% of peak
Brain / plasma AUC ratio—1.24 ×
Dose—5 mg/kg
FIG. 01Mixed · normalized illustrative

Exposure peaks at 0.5 h and falls below 5% of peak by 6 h.

Lieflat Basics F2 hairline-line structure. Solid points show source constraints. Continuous profiles are normalized illustrative reconstructions, not measured intermediate concentrations.
Normalized plasma and brain exposure illustration Peak at 0.5 hours and below 5 percent at 6 hours. Continuous hairlines are normalized illustrations.0 h0.5 h1 h2 h4 h6 h8 hnormalized peak = 100one dot = one illustrative sample0.5 h peak<5% @ 6 h1.24×brain AUC / plasma AUC

Interpretation

The exposure figure is a normalized visual reconstruction of source-reported constraints, not an absolute concentration-time dataset.

Limitations

  • Absolute concentrations and pharmacokinetic parameters such as Cmax, half-life, clearance and volume of distribution are not mapped in v1.
0.5 hPeakSource reported
1.24×Brain AUCvs plasma AUC
5 mg/kgDose contextSource reported
Continue exploring
01One canvas. Three connected directions.An interactive, source-aware mechanism narrative across vascular response, neurovascular recovery and neuroprotection.02Aildenafil phosphate, presented with precision.A source-mapped product profile for Aildenafil phosphate tablets, separated from the evidence library.03A precise route for scientific questions.A static first medical-information contact path for evidence and safety questions.